Dihydroergotamine Mesylate

Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agreement - Pulmatrix advances existing discussions on alternative merger opportunities - FRAMINGHAM, Mass., March 2, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced that on February 28, 2026, Cullgen Inc. notified Pulmatrix that Cullgen was terminating the Merger Agreement (as defined herein) and related transactions thereunder. This termination follows the December 2025 press release announcing that Pulmatrix and Cullgen had mutually agreed to waive the "No Solicitation" clause in the Merger Agreement in order to permit each party to explore alternate transactions in the period until closing. At this time, Pulmatrix continues to pursue alternative merger opportunities. Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, "Due to the significant delays at the Chinese Regulatory Authority (CSRC) in 2025, we initiated a process earlier this year to identify an alternative reverse merger opportunity for the Company, and we are encouraged by both the interest we've had to date as well as the recent increase in transaction activity within our industry." Prior Proposed Merger with Cullgen As previously reported, on November 13, 2024, the Company entered into an agreement and plan of merger with Cullgen, as amended by Amendment No. 1 thereto on April 7, 2025 (the "Merger Agreement" and the transactions contemplated thereunder, collectively, the "Merger"). Additional information about the Merger Agreement and the previously proposed Merger was previously disclosed in a registration statement on Form S-4 (File No. 333-284993) initially filed with the Securities and Exchange Commission (the "SEC") on February 14, 2025, as amended on April 17, 2025, and May 7, 2025, and declared effective on May 9, 2025. On June 16, 2025, the Company held a special meeting in lieu of the annual meeting of Pulmatrix stockholders, at which meeting the Company's stockholders approved the Merger and related proposals. The closing of the Merger was subject to certain closing conditions, including approval from the China Security Regulatory Commission which had not been obtained at the time of Cullgen's termination. Pulmatrix Clinical Assets and Proprietary iSPERSE™ Technology iSPERSE™ Technology iSPERSE™, also licensed to MannKind Corporation and Cipla Technologies for certain fields of use, utilizes particles that are engineered with a small, dense and dispersible profile to exceed the performance of traditional dry powder particles as the iSPERSE™ particles have the dispersibility advantages of porous engineered particles. Pulmatrix believes this results in superior drug delivery compared to traditional oral and injectable forms of treatment for certain diseases. As of December 31, 2025, Pulmatrix's patent portfolio related to iSPERSE™ included approximately 149 granted patents, 18 of which are U.S.-granted patents, plus approximately 48 pending patent applications in the U.S. and other jurisdictions. PUR3100 PUR3100, a Phase 2-ready asset, is an orally inhaled dihydroergotamine ("DHE") engineered with Pulmatrix's iSPERSE™ dry powder inhalation technology for the treatment of acute migraine has a Food and Drug Administration acceptance of an Investigational New Drug ("IND") application for PUR3100 and receipt of a "study may proceed" letter to proceed with a Phase 2 study. The IND includes a Phase 2 clinical protocol where safety and preliminary efficacy of PUR3100 will be investigated in patients with acute migraine. The Phase 2 IND builds on the Phase 1 trial results of PUR3100, which were published in 2024 in the peer-reviewed publication, Headache: The Journal of Head and Face Pain. The study showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time to maximum concentration occurred at five minutes after dosing at all dosing levels. The PUR3100 dose groups also showed a lower incidence of nausea and no vomiting compared to observations of nausea and vomiting in the intravenously ("IV") administered DHE dose group. PUR1800 PUR1800 is a Narrow Spectrum Kinase Inhibitor ("NSKI"), engineered with our iSPERSE™ technology, for the treatment of acute exacerbations in chronic obstructive pulmonary disease ("AECOPD"). In 2023, Pulmatrix presented complete results from a Phase 1b study of PUR1800 for AECOPD, indicating PUR1800 was well-tolerated with no observed safety signals. The topline data, along with the results from chronic toxicology studies, support the continued development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory diseases. In 2024, Pulmatrix published an abstract titled "Ex vivo evaluation of the potential for Narrow Spectrum Kinase inhibitors as a treatment for Idiopathic Pulmonary Fibrosis". PUR1900 PUR1900, approved to proceed to a Phase 3 in India conducted by our partner Cipla, is the Company's inhaled iSPERSE™ formulation of the antifungal drug itraconazole being investigated for various indications. The Company and its partner, Cipla, wound down a Phase 2b trial that the Company was operating in 2024. Cipla has continued clinical development outside the United States, and in 2025 completed their Phase 2 study in India and have been approved by India's Central Drug Standard Control Organization to proceed with a Phase 3 clinical trial. Pulmatrix will receive 2% royalties on any potential future net sales by Cipla outside the United States should Cipla successfully market PUR1900 outside the United States. Within the United States, the Company and Cipla share the rights 50/50 and will seek to monetize PUR1900 for indications where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet medical need. About Pulmatrix, Inc. Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. For more on the Company's inhaled product candidates please visit: . Forward-Looking Statements Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that," "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the consummation of any other potential reverse merger transaction in the future, among others; the Company's ability to divest its clinical assets on terms favorable to the Company, or at all, the Company's ability to maintain compliance with the listing standards of the Nasdaq Capital Market; the Company's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, including the proposed Merger with Cullgen, is set forth in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Investor Contact: Chuck Padala Managing Director LifeSci Advisors 646-627-8390 [email protected] SOURCE Pulmatrix Inc. 21% more press release views with Request a Demo

‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million , Adjusted EBITDA of $175 million ; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion ; GAAP Net Income of $72 million ; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million ; Adjusted EBITDA of $688 million ; Adjusted Diluted EPS of $0.83 ‒ ‒ Provides 2026 Financial Guidance of $3.05 to $3.15 billion in net revenue, $720 to $760 million in Adjusted EBITDA, and $0.93 to $1.03 in Adjusted Diluted EPS – BRIDGEWATER, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2025. “We are extremely pleased with Amneal’s sixth consecutive year of consistent execution and strong growth. Our full year 2025 performance highlights the durability of our diversified portfolio and the successful execution of our strategy. In Specialty, CREXONT® continues to see strong uptake, and we successfully launched our newest branded product, the BREKIYA® autoinjector. In Affordable Medicines, we delivered a robust cadence of new product approvals, including our first two inhalation products and our fourth and fifth biosimilars. Looking ahead, we believe Amneal is very well positioned to deliver substantial growth and create long-term value for years to come,” said Chirag and Chintu Patel, Co-Chief Executive Officers. Net revenue in the fourth quarter of 2025 was $814 million, an increase of 11% compared to $731 million in the fourth quarter of 2024. Specialty net revenue increased 38% driven by CREXONT® and UNITHROID®. Affordable Medicines net revenue decreased 1% due to the timing of revenue for key products and new launches. AvKARE net revenue increased 24% driven by growth in the government label sales channel. Net income attributable to Amneal Pharmaceuticals, Inc. was $35 million in the fourth quarter of 2025 compared to a net loss of $31 million in the fourth quarter of 2024, reflecting higher revenue and gross profit and lower operating expense. Adjusted EBITDA in the fourth quarter of 2025 was $175 million, an increase of 13% compared to the fourth quarter of 2024, reflective of higher revenue and gross profit, partially offset by commercial investments. Diluted income per share in the fourth quarter of 2025 was $0.11 compared to a loss of $0.10 for the fourth quarter of 2024 due to the aforementioned factors as well as lower interest expense. Adjusted diluted EPS in the fourth quarter of 2025 was $0.21 compared to $0.12 in the fourth quarter of 2024. Net revenue for the year ended December 31, 2025 was $3.02 billion, an increase of 8%, compared to $2.79 billion for the year ended December 31, 2024. Revenues for each of the business segments increased in 2025 with Specialty growing 19%, Affordable Medicines growing 4%, and AvKARE growing 12%. Net income attributable to Amneal Pharmaceuticals, Inc. was $72 million for the year ended December 31, 2025 compared to a net loss of $117 million for the year ended December 31, 2024, due to higher revenue and gross profit, and lower expenses. Adjusted EBITDA for the year ended December 31, 2025 was $688 million, an increase of 10% compared to the prior year, reflective of higher revenue and gross profit and operating leverage in selling, general and administrative expenses and research and development expenses, partially offset by increased commercial investments. Diluted income per share for the year ended December 31, 2025 was $0.22 compared to diluted loss per share of $0.38 for the year ended December 31, 2024 due to the aforementioned factors as well as lower interest expense. Adjusted diluted EPS in the year ended December 31, 2025 was $0.83 compared to $0.58 for the year ended December 31, 2024. The Company presents GAAP and adjusted (non-GAAP) quarterly and full-year results. Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information. 2026 Full Year Financial Guidance 2026 Guidance 2025 Actuals Net revenue (1) $3.05 billion - $3.15 billion $3.02 billion Adjusted EBITDA (2) $720 million - $760 million $688 million Adjusted diluted EPS (3) $0.93 - $1.03 $0.83 Operating cash flow $325 million - $375 million $340 million Operating cash flow, excluding discrete items (4) $350 million - $400 million $340 million Capital expenditures (5) ~$110 million $89 million (1) The Company expects Affordable Medicines net revenue to grow 7% to 8%, Specialty net revenue to be flat year-over-year, and AvKARE to generate $625 million to $700 million net revenue. (2) Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below. (3) Accounts for 35% non-controlling interest in AvKARE. Assumes weighted-average diluted shares outstanding of ~330 million for the year ending December 31, 2026, compared to weighted-average diluted shares outstanding of 325 million for the year ended December 31, 2025. See also “Non-GAAP Financial Measures” below for assumptions used in the calculation of weighted-average diluted shares. (4) Excludes discrete items such as legal settlement payments. (5) Reflects actual purchases and deposits for future acquisition of property, plant, and equipment, net of contributions from an alliance party. Amneal’s 2026 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results. Conference Call Information Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, February 27, 2026, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at To access the call through a conference line, dial (833) 470-1428 (in the U.S.) with access code 937407. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail, injectable, and biosimilar products. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit and follow us on LinkedIn. Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; statements regarding our positioning and potential growth, statements regarding our ability to create long-term value, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reform and changes in coverage and reimbursement levels and funding by governmental authorities and other third-party payers; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. Non-GAAP Financial Measures This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted operating cash flow and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP. Adjusted diluted EPS reflects diluted earnings per share based on adjusted net income (loss), which is net income (loss) adjusted to (A) exclude (i) non-cash interest, (ii) GAAP provision for income taxes, (iii) amortization, (iv) stock-based compensation expense, (v) acquisition, site closure expenses, and idle facility expenses, (vi) restructuring and other charges, (vii) loss on refinancing, (viii) charges (credit) related to certain legal matters, including interest, net, (ix) asset impairment charges, (x) increase in tax receivable agreement liability, (xi) other and (xii) net income attributable to non-controlling interests, and (B) include non-GAAP provision for income taxes. Non-GAAP adjusted diluted EPS for the three months and year ended December 31, 2025 and 2024 was calculated using the weighted average fully diluted shares outstanding of Class A common stock (inclusive of the effect of dilutive securities). EBITDA reflects net income (loss) adjusted to exclude interest expense, net, provision for income taxes and depreciation and amortization. Adjusted EBITDA reflects net income (loss) adjusted to exclude (i) interest expense, net, (ii) provision for income taxes, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) acquisition, site closure, and idle facility expenses, (vi) restructuring and other charges, (vii) loss on refinancing, (viii) charges (credit) related to legal matters, net, (ix) asset impairment charges, (x) foreign exchange loss (gain), (xi) increase in tax receivable agreement liability, and (xii) other. Adjusted operating cash flow reflects cash flow from operations excluding discrete items such as legal settlement payments. Net leverage is calculated as net debt (total outstanding principal on the Company’s debt, less cash and cash equivalents) divided by adjusted EBITDA for the year or the trailing twelve-month period then ended. Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management. These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below and should not rely on any single financial measure to evaluate the Company’s business. A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below. Contact Anthony DiMeo VP, Investor Relations anthony.dimeo@amneal.com Amneal Pharmaceuticals, Inc. Consolidated Statements of Operations (unaudited; $ in thousands, except per share amounts) Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Net revenue $ 814,319 $ 730,518 $ 3,018,760 $ 2,793,957 Cost of goods sold 517,129 467,645 1,905,452 1,773,519 Gross profit 297,190 262,873 1,113,308 1,020,438 Selling, general and administrative 146,458 128,687 526,827 476,436 Research and development 34,819 54,265 186,175 190,714 Intellectual property legal development expenses 1,411 1,852 7,632 5,845 Restructuring and other charges 2,470 493 4,208 2,355 Charges (credit) related to legal matters, net — 1,783 (390 ) 96,692 Other operating income (1 ) — (5,240 ) (930 ) Operating income 112,033 75,793 394,096 249,326 Other (expense) income: Interest expense, net (56,237 ) (61,662 ) (241,091 ) (258,595 ) Foreign exchange (loss) gain, net (1,437 ) (7,661 ) 7,635 (6,846 ) Loss on refinancing — — (31,365 ) — Increase in tax receivable agreement liability (12,289 ) (23,961 ) (6,588 ) (50,680 ) Other income, net 13,165 2,172 16,522 11,782 Total other expense, net (56,798 ) (91,112 ) (254,887 ) (304,339 ) Income (loss) before income taxes 55,235 (15,319 ) 139,209 (55,013 ) Provision for income taxes 5,662 5,423 11,276 18,863 Net income (loss) 49,573 (20,742 ) 127,933 (73,876 ) Less: Net income attributable to non-controlling interests (14,497 ) (10,339 ) (55,876 ) (43,010 ) Net income (loss) attributable to Amneal Pharmaceuticals, Inc. $ 35,076 $ (31,081 ) $ 72,057 $ (116,886 ) Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders: Basic $ 0.11 $ (0.10 ) $ 0.23 $ (0.38 ) Diluted $ 0.11 $ (0.10 ) $ 0.22 $ (0.38 ) Weighted-average common shares outstanding: Basic 314,462 309,850 313,367 308,978 Diluted 328,094 309,850 324,805 308,978 Amneal Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (unaudited; $ in thousands) December 31, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 282,029 $ 110,552 Restricted cash 28,842 7,868 Trade accounts receivable, net 895,143 775,731 Inventories 606,302 612,454 Prepaid expenses and other current assets 98,395 80,717 Related party receivables 470 484 Total current assets 1,911,181 1,587,806 Property, plant and equipment, net 442,950 424,908 Goodwill 595,470 597,436 Intangible assets, net 563,498 732,377 Operating lease right-of-use assets 38,832 31,388 Operating lease right-of-use assets - related party 15,216 10,964 Financing lease right-of-use assets 53,328 56,433 Other assets 57,805 60,133 Total assets $ 3,678,280 $ 3,501,445 Liabilities and Stockholders’ Deficiency Current liabilities: Accounts payable and accrued expenses $ 761,316 $ 735,450 Current portion of liabilities for legal matters 43,256 31,755 Revolving credit facility — 100,000 Current portion of long-term debt, net 6,761 224,213 Current portion of operating lease liabilities 8,668 9,435 Current portion of operating lease liabilities - related party 2,705 3,396 Current portion of financing lease liabilities 3,442 3,211 Related party payables - short term 55,485 22,311 Total current liabilities 881,633 1,129,771 Long-term debt, net 2,565,115 2,161,790 Operating lease liabilities 33,233 24,814 Operating lease liabilities - related party 14,195 9,391 Financing lease liabilities 54,927 56,889 Related party payable - long term 19,132 50,900 Liabilities for legal matters - long term 71,819 85,479 Other long-term liabilities 32,263 26,949 Total long-term liabilities 2,790,684 2,416,212 Redeemable non-controlling interests 77,292 64,974 Total stockholders’ deficiency (71,329 ) (109,512 ) Total liabilities and stockholders’ deficiency $ 3,678,280 $ 3,501,445 Amneal Pharmaceuticals, Inc. Consolidated Statements of Cash Flows (unaudited; $ in thousands) Years Ended December 31, 2025 2024 Cash flows from operating activities: Net income (loss) $ 127,933 $ (73,876 ) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 223,572 236,191 Unrealized foreign currency (gain) loss (7,453 ) 7,191 Amortization of debt issuance costs and discount 22,431 29,097 Reclassification of cash flow hedge 1,229 (26,205 ) Loss on refinancing 31,365 — Intangible asset impairment charges 22,784 920 Stock-based compensation 31,953 27,768 Inventory provision 85,962 96,558 Other operating charges and credits, net 4,732 1,523 Changes in assets and liabilities: Trade accounts receivable, net (120,566 ) (162,637 ) Inventories (87,026 ) (130,530 ) Prepaid expenses, other current assets and other assets (19,163 ) (959 ) Related party receivables (13 ) 482 Accounts payable, accrued expenses and other liabilities 21,321 235,135 Related party payables 931 54,441 Net cash provided by operating activities 339,992 295,099 Cash flows from investing activities: Purchases of property, plant and equipment (70,063 ) (51,924 ) Acquisition of intangible assets (15,514 ) (14,650 ) Deposits for future acquisition of property, plant, and equipment (28,780 ) (8,416 ) Proceeds from sale of property, plant, equipment and other 2,094 — Proceeds from sale of subsidiary — 11,994 Net cash used in investing activities (112,263 ) (62,996 ) Cash flows from financing activities: Proceeds from issuance of debt 2,694,750 — Payments of principal on debt, revolving credit facility, financing leases and other (2,811,508 ) (188,918 ) Payments of deferred financing, refinancing costs and debt extinguishment costs (74,973 ) (71 ) Borrowings on revolving credit facility 218,000 48,000 Proceeds from exercise of stock options 1,960 1,154 Employee payroll tax withholding on restricted stock unit and performance stock unit vesting (22,278 ) (7,952 ) Tax and other distributions to non-controlling interests (43,848 ) (19,804 ) Payment of principal on notes payable - related party — (44,200 ) Proceeds from alliance party 6,367 — Net cash used in financing activities (31,530 ) (211,791 ) Effect of foreign exchange rate on cash (1,680 ) (999 ) Net increase in cash, cash equivalents, and restricted cash 194,519 19,313 Cash, cash equivalents, and restricted cash - beginning of period 118,420 99,107 Cash, cash equivalents, and restricted cash - end of period $ 312,939 $ 118,420 Cash and cash equivalents - end of period $ 282,029 $ 110,552 Restricted cash - end of period 28,842 7,868 Long-term restricted cash included in other assets - end of period 2,068 — Cash, cash equivalents, and restricted cash - end of period $ 312,939 $ 118,420 Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited, $ in thousands) Reconciliation of Net Income (Loss) to EBITDA and Adjusted EBITDA Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Net income (loss) $ 49,573 $ (20,742 ) $ 127,933 $ (73,876 ) Adjusted to add: Interest expense, net 56,237 61,662 241,091 258,595 Provision for income taxes 5,662 5,423 11,276 18,863 Depreciation and amortization 49,227 66,130 223,572 236,191 EBITDA (Non-GAAP) $ 160,699 $ 112,473 $ 603,872 $ 439,773 Adjusted to add (deduct): Stock-based compensation expense 8,202 7,209 31,823 27,552 Acquisition, site closure, and idle facility expenses (1) 539 538 5,301 2,112 Restructuring and other charges 2,470 493 4,208 2,265 Loss on refinancing (2) — — 31,365 — Charges (credit) related to legal matters, net (3) — 1,783 (390 ) 96,692 Asset impairment charges 134 176 23,022 1,372 Foreign exchange loss (gain) 1,437 7,661 (7,635 ) 6,846 Increase in tax receivable agreement liability 12,289 23,961 6,588 50,680 Other (4) (10,568 ) 963 (9,739 ) 150 Adjusted EBITDA (Non-GAAP) $ 175,202 $ 155,257 $ 688,415 $ 627,442 Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited, $ in thousands) Calculation of Net Debt and Net Leverage December 31, 2025 December 31, 2024 Term Loan Due 2032 $ 2,094,750 $ — Senior Notes Due 2032 600,000 — Term Loan Due 2025 — 191,979 Term Loan Due 2028 — 2,292,856 Revolving credit facility — 100,000 Gross debt (5) $ 2,694,750 $ 2,584,835 Less: Cash and cash equivalents 282,029 110,552 Net debt (Non-GAAP) (6) $ 2,412,721 $ 2,474,283 Adjusted EBITDA (Non-GAAP) for the year ended $ 688,415 $ 627,442 Net leverage (Non-GAAP) (7) 3.5x 3.9x Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited; $ in thousands, except per share amounts) Reconciliation of Net Income (Loss) to Adjusted Net Income and Calculation of Adjusted Diluted Earnings per Share Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Net income (loss) $ 49,573 $ (20,742 ) $ 127,933 $ (73,876 ) Adjusted to add (deduct): Non-cash interest 6,625 183 23,533 1,735 GAAP provision for income taxes 5,662 5,423 11,276 18,863 Amortization 34,660 49,037 162,401 168,518 Stock-based compensation expense 8,202 7,209 31,823 27,552 Acquisition, site closure expenses, and idle facility expenses (1) 538 538 5,238 2,112 Restructuring and other charges 2,470 493 4,201 2,249 Loss on refinancing (2) — — 31,365 — Charges (credit) related to legal matters, including interest, net (3) — 1,783 (390 ) 96,819 Asset impairment charges 134 176 23,022 1,372 Increase in tax receivable agreement liability 12,289 23,961 6,588 50,680 Other (4) (10,568 ) 964 (9,729 ) 150 Provision for income taxes (8) (26,792 ) (18,262 ) (92,514 ) (66,278 ) Net income attributable to non-controlling interests (14,497 ) (10,339 ) (55,876 ) (43,010 ) Adjusted net income (Non-GAAP) $ 68,296 $ 40,424 $ 268,871 $ 186,886 Weighted average diluted shares outstanding (Non-GAAP) (9) 328,094 324,099 324,805 320,645 Adjusted diluted earnings per share (Non-GAAP) $ 0.21 $ 0.12 $ 0.83 $ 0.58 Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited) Explanations for Non-GAAP Reconciliations (1) Acquisition, site closure, and idle facility expenses for the three months and year ended December 31, 2025 primarily included costs related to a planned facility closure and rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three months and year ended December 31, 2024 primarily included rent for vacated properties. (2) For the year ended December 31, 2025, loss on refinancing was primarily comprised of debt issuance costs associated with the portion of the Term Loan Due 2028 that was modified as part of the Company’s debt refinancing on August 1, 2025. Refer to Note 5. below for additional information. (3) For the year ended December 31, 2024, charges related to legal matters, net were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by political subdivisions and Native American tribes across the United States. (4) For the three months and year ended December 31, 2025, the caption “other” primarily reflects a non-recurring, non-operating, non-cash gain. System implementation expense of $0.3 million, formerly included in its own caption in the non-GAAP reconciliations, for the three months ended December 31, 2024 has been reclassified to the caption “other” to conform to the current period presentation. System implementation expense of $2.4 million and change in the fair value of contingent consideration of ($0.9 million), formerly included in their own captions in the non-GAAP reconciliations, for the year ended December 31, 2024 have been reclassified to the caption “other” to conform to the current period presentation. (5) On August 1, 2025, the Company borrowed $2.1 billion under new seven-year term loans (the “Term Loan Due 2032”) pursuant to an amendment to the Term Loan Credit Agreement and completed a private offering of $600 million aggregate principal amount of 6.875% senior secured notes due 2032 at par (the “Senior Notes Due 2032”). The Company used the net proceeds of the Term Loan Due 2032 and the Senior Notes Due 2032 to refinance the Term Loan Due 2028 in full, to repay outstanding amounts borrowed under the revolving credit facility in full, and to pay related fees, premiums and expenses. Refer to Note 15. Debt in the Company’s 2024 Annual Report on Form 10-K for information about the Company’s debt as of December 31, 2024. (6) Net debt was calculated as the total outstanding principal on the Company’s debt less cash and cash equivalents. (7) Net leverage was calculated by dividing net debt as of December 31, 2025 and December 31, 2024 by adjusted EBITDA for the years ended December 31, 2025 and 2024, respectively. (8) The non-GAAP effective tax rates for the three months and year ended December 31, 2025 were 28.2% and 25.6%, respectively. The non-GAAP effective tax rates for the three months and year ended December 31, 2024 were 31.1% and 26.2%, respectively. (9) Weighted average diluted shares outstanding for the three months and year ended December 31, 2025 and 2024 consisted of fully diluted Class A common stock (inclusive of the effect of dilutive securities). Amneal Pharmaceuticals, Inc. Affordable Medicines Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands) Three Months Ended December 31, 2025 Three Months Ended December 31, 2024 As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP Net revenue $ 436,650 $ — $ 436,650 $ 439,296 $ — $ 439,296 Cost of goods sold (2) 285,858 (11,288 ) 274,570 261,196 (11,595 ) 249,601 Gross profit 150,792 11,288 162,080 178,100 11,595 189,695 Gross margin % 34.5 % 37.1 % 40.5 % 43.2 % Selling, general and administrative (3) 37,269 (2,472 ) 34,797 33,915 (1,909 ) 32,006 Research and development (4) 28,010 (671 ) 27,339 48,598 (674 ) 47,924 Intellectual property legal development expenses 1,320 — 1,320 1,907 — 1,907 Restructuring and other charges 2,198 (2,198 ) — — — — Charges related to legal matters, net — — — 1,783 (1,783 ) — Other operating income (1 ) — (1 ) — — — Operating income $ 81,996 $ 16,629 $ 98,625 $ 91,897 $ 15,961 $ 107,858 (1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment. (2) Adjustments for the three months ended December 31, 2025 and 2024, respectively, were comprised of stock-based compensation expense ($0.9 million in each period), amortization expense ($10.4 million and $10.6 million), and asset impairment charges (none and $0.1 million). (3) Adjustments for the three months ended December 31, 2025 and 2024, respectively, were comprised of stock-based compensation expense ($1.8 million and $1.4 million), site closure costs ($0.5 million in each period), and asset impairment charges ($0.2 million and none). (4) Adjustments for the three months ended December 31, 2025 and 2024 were comprised of stock-based compensation expense. Amneal Pharmaceuticals, Inc. Affordable Medicines Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands) Year Ended December 31, 2025 Year Ended December 31, 2024 As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP Net revenue $ 1,745,524 $ — $ 1,745,524 $ 1,685,263 $ — $ 1,685,263 Cost of goods sold (2) 1,061,600 (45,409 ) 1,016,191 1,011,363 (46,718 ) 964,645 Gross profit 683,924 45,409 729,333 673,900 46,718 720,618 Gross margin % 39.2 % 41.8 % 40.0 % 42.8 % Selling, general and administrative (3) 142,383 (8,812 ) 133,571 129,578 (7,160 ) 122,418 Research and development (4) 156,013 (2,816 ) 153,197 171,771 (2,587 ) 169,184 Intellectual property legal development expenses 7,389 — 7,389 5,685 — 5,685 Restructuring and other charges 2,971 (2,971 ) — 70 (70 ) — (Credit) charges related to legal matters, net (5) (390 ) 390 — 96,692 (96,692 ) — Other operating income (5,240 ) — (5,240 ) — — — Operating income $ 380,798 $ 59,618 $ 440,416 $ 270,104 $ 153,227 $ 423,331 (1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment. (2) Adjustments for the years ended December 31, 2025 and 2024, respectively, were comprised of stock-based compensation expense ($3.8 million and $3.6 million), amortization expense ($40.9 million and $41.8 million), and asset impairment charges ($0.7 million and $1.3 million). (3) Adjustments for the years ended December 31, 2025 and 2024, respectively, were comprised of stock-based compensation expense ($6.5 million and $5.1 million), site closure expenses ($2.1 million in each period), and asset impairment charges ($0.2 million and none). (4) Adjustments for the years ended December 31, 2025 and 2024 were comprised of stock-based compensation expense. (5) Adjustment for the year ended December 31, 2024 was primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by political subdivisions and Native American tribes across the United States. Amneal Pharmaceuticals, Inc. Specialty Segment Reconciliation of GAAP to Non-GAAP Operating Results (unaudited; $ in thousands) Three Months Ended December 31, 2025 Three Months Ended December 31, 2024 As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP Net revenue $ 166,928 $ — $ 166,928 $ 120,836 $ — $ 120,836 Cost of goods sold (1) 63,229 (22,586 ) 40,643 59,537 (36,224 ) 23,313 Gross profit 103,699 22,586 126,285 61,299 36,224 97,523 Gross margin % 62.1 % 75.7 % 50.7 % 80.7 % Selling, general and administrative (2) 40,843 (491 ) 40,352 30,129 (293 ) 29,836 Research and development (2) 6,809 (81 ) 6,728 5,667 (257 ) 5,410 Intellectual property legal development expenses 91 — 91 (55 ) — (55 ) Restructuring and other charges — — — 493 (493 ) — Operating income $ 55,956 $ 23,158 $ 79,114 $ 25,065 $ 37,267 $ 62,332 (1) Adjustments for the three months ended December 31, 2025 and 2024 were comprised of amortization expense. (2) Adjustments for the three months ended December 31, 2025 and 2024 were comprised of stock-based compensation expense. Amneal Pharmaceuticals, Inc. Specialty Segment Reconciliation of GAAP to Non-GAAP Operating Results (unaudited; $ in thousands) Year Ended December 31, 2025 Year Ended December 31, 2024 As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP Net revenue $ 528,508 $ — $ 528,508 $ 445,749 $ — $ 445,749 Cost of goods sold (1) 245,915 (136,713 ) 109,202 202,821 (117,573 ) 85,248 Gross profit 282,593 136,713 419,306 242,928 117,573 360,501 Gross margin % 53.5 % 79.3 % 54.5 % 80.9 % Selling, general and administrative (2) 135,715 (1,812 ) 133,903 109,658 (1,048 ) 108,610 Research and development (3) 30,162 (3,511 ) 26,651 18,943 (1,058 ) 17,885 Intellectual property legal development expenses 243 — 243 160 — 160 Restructuring and other charges 471 (471 ) — 1,517 (1,517 ) — Other operating income — — — (930 ) 930 — Operating income $ 116,002 $ 142,507 $ 258,509 $ 113,580 $ 120,266 $ 233,846 (1) Adjustments for the years ended December 31, 2025 and 2024, respectively, were comprised of amortization expense ($114.6 million and $117.6 million) and asset impairment charges ($22.1 million and none). (2) Adjustments for the years ended December 31, 2025 and 2024 were comprised of stock-based compensation expense. (3) Adjustments for the years ended December 31, 2025 and 2024, respectively, were comprised of stock-based compensation expense ($0.4 million and $1.1 million) and site closure costs ($3.1 million and none). Amneal Pharmaceuticals, Inc. AvKARE Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands) Three Months Ended December 31, 2025 Three Months Ended December 31, 2024 As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP Net revenue $ 210,741 $ — $ 210,741 $ 170,386 $ — $ 170,386 Cost of goods sold 168,042 — 168,042 146,912 — 146,912 Gross profit 42,699 — 42,699 23,474 — 23,474 Gross margin % 20.3 % 20.3 % 13.8 % 13.8 % Selling, general and administrative (2) 17,169 (2,700 ) 14,469 16,015 (3,546 ) 12,469 Operating income $ 25,530 $ 2,700 $ 28,230 $ 7,459 $ 3,546 $ 11,005 (1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment. (2) Adjustments for the three months ended December 31, 2025 and 2024 were comprised of amortization expense. Amneal Pharmaceuticals, Inc. AvKARE Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands) Year Ended December 31, 2025 Year Ended December 31, 2024 As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP Net revenue $ 744,728 $ — $ 744,728 $ 662,945 $ — $ 662,945 Cost of goods sold 597,937 — 597,937 559,335 — 559,335 Gross profit 146,791 — 146,791 103,610 — 103,610 Gross margin % 19.7 % 19.7 % 15.6 % 15.6 % Selling, general and administrative (2) 63,176 (10,799 ) 52,377 60,709 (14,182 ) 46,527 Operating income $ 83,615 $ 10,799 $ 94,414 $ 42,901 $ 14,182 $ 57,083 (1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment. (2) Adjustments for the years ended December 31, 2025 and 2024 were comprised of amortization expense.